Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia

Serial studies have demonstrated that induction therapy with FLAM [flavopiridol (alvocidib) 50 mg/m(2) days 1–3, cytarabine 667 mg/m(2)/day continuous infusion days 6–8, and mitoxantrone (FLAM) 40 mg/m(2) day 9] yields complete remission rates of nearly 70% in newly diagnosed poor-risk acute myeloid...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Zeidner, Joshua F., Foster, Matthew C., Blackford, Amanda L., Litzow, Mark R., Morris, Lawrence E., Strickland, Stephen A., Lancet, Jeffrey E., Bose, Prithviraj, Levy, M. Yair, Tibes, Raoul, Gojo, Ivana, Gocke, Christopher D., Rosner, Gary L., Little, Richard F., Wright, John J., Doyle, L. Austin, Smith, B. Douglas, Karp, Judith E.
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2015
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4800702/
https://ncbi.nlm.nih.gov/pubmed/26022709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.125849
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados